The “why” behind every decision is the person in front of us. In this conversation, I joined the Leap Together podcast to discuss the real-world complexity for patients living with pulmonary fibrosis.
Listen here: lpcur.com/LeapTogether...
#LeapTogetherPodcast #ClinicalTrials #curePF
Screen shot of title page
The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study
Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)
#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...
The approval of Nerandomilast marks a pivotal step forward in IPF care. For patients living with IPF, this offers long awaited hope and this milestone underscores the collective efforts of multiple stakeholders who never stopped pushing for better therapeutic options for IPF.
Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...
Text of primary and secondary endpoints
TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁
Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD
@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
www.theglobeandmail.com/investing/ma...
Heading to #ATS2025 🫁?
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁
@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social
Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....
Had the same question when I saw this paper- typically co-manage SSc patients with our rheumatology colleagues and ILD team are predominant prescribers for Nintedanib.
Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...
Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?
Hope so! Especially since there seems to be an efficacy signal.
The ATS CP apprenticeship program is a great way to get involved with the assembly!
Get more info and apply here:
tinyurl.com/439v6xam
Make sure to select the clinical problems assembly and apply before January 24!⏰
#pulmsky #medsky
Screenshot of the article title and authors
🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Happy New Year!
Please add me too! #CurePF
screenshot of study title. Effects of nintedanib on biomarkers in IPF in ERJ Open.
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
An excellent 🧵on potential application of Mendelian randomization towards target identification and therapeutic development #cureIPF #REMAP-ILD
There’s still time to submit session ideas for #CHEST2025! Don't miss your chance to speak! Need help? Just ask me! info.chestnet.org/chest-call-f...
👆I feel like if it is used responsibly to aid with language (and not the underlying science), there might be precedence to allow it- wouldn’t it be easy to implement this though.
🙋♀️
👋 I'm a pulmonary critical care physician and ILD specialist at UAB. Within ATS, I'm active in the Clinical Problems Assembly!
Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF
Continued awareness and identification of IPF needs to continue.
🙋♀️
So excited to hear what @kerrijohannson.bsky.social has to tell us about the impact of our environment on the development of pulmonary fibrosis! The whole lecture will be available on-line via the MTW website: www.imperial.ac.uk/mtw-centre-f...
Cover of AJRCCM
Really cool! our “Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis” made it to cover of the American Journal of Respiratory & Critical Care Medicine. Kudos to soon to be #DoubleDoc Amy Zhao & crew!! #BestStudents www.atsjournals.org/doi/full/10....
Made my first pilgrimage to ACCP in Glenview, IL this week. Thanks #Chest for the hospitality! @tkulkarni.bsky.social
